Study Exclusion Criteria Limits RealWorld Benefit of Immunotherapy in Lung Cancer

Study Exclusion Criteria Limits Real-World Benefit of Immunotherapy in Lung Cancer

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

More From BioPortfolio on "Study Exclusion Criteria Limits Real-World Benefit of Immunotherapy in Lung Cancer"